Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
mi
from
Allentown, PA
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
mi
from
Allentown, PA
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
Geisinger Medical Center
mi
from
Danville, PA
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
Geisinger Medical Group
mi
from
State College, PA
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Geisinger Medical Group
mi
from
State College, PA
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
Avera McKennan Hospital and University Health Center
mi
from
Sioux Falls, SD
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Avera McKennan Hospital and University Health Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
Medical X-Ray Center, P. C.
mi
from
Sioux Falls, SD
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Medical X-Ray Center, P. C.
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
Sioux Valley Hospital at University of South Dakota Medical Center
mi
from
Sioux Falls, SD
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Sioux Valley Hospital at University of South Dakota Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
Franciscan Skemp Healthcare
mi
from
La Crosse, WI
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Franciscan Skemp Healthcare
mi
from
La Crosse, WI
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
Allan Blair Cancer Centre at Pasqua Hospital
mi
from
Regina,
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Allan Blair Cancer Centre at Pasqua Hospital
mi
from
Regina,
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Graham Hospital
mi
from
Canton, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Graham Hospital
mi
from
Canton, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Memorial Hospital
mi
from
Carthage, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Eureka Community Hospital
mi
from
Eureka, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Eureka Community Hospital
mi
from
Eureka, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Mason District Hospital
mi
from
Havana, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Mason District Hospital
mi
from
Havana, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Hopedale Medical Complex
mi
from
Hopedale, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Hopedale Medical Complex
mi
from
Hopedale, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Kewanee Hospital
mi
from
Kewanee, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Kewanee Hospital
mi
from
Kewanee, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
McDonough District Hospital
mi
from
Macomb, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
McDonough District Hospital
mi
from
Macomb, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Community Cancer Center
mi
from
Normal, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Community Cancer Center
mi
from
Normal, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
OSF Saint Elizabeth Medical Center
mi
from
Ottawa, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
OSF Saint Elizabeth Medical Center
mi
from
Ottawa, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Cancer Treatment Center at Pekin Hospital
mi
from
Pekin, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Cancer Treatment Center at Pekin Hospital
mi
from
Pekin, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Proctor Hospital
mi
from
Peoria, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Proctor Hospital
mi
from
Peoria, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
OSF St. Francis Medical Center
mi
from
Peoria, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
OSF St. Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Illinois Valley Community Hospital
mi
from
Peru, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Illinois Valley Community Hospital
mi
from
Peru, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
St. Margaret's Hospital
mi
from
Spring Valley, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
St. Margaret's Hospital
mi
from
Spring Valley, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Carle Cancer Center at Carle Foundation Hospital
mi
from
Urbana, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Carle Cancer Center at Carle Foundation Hospital
mi
from
Urbana, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Saint Anthony Memorial Health Centers
mi
from
Michigan City, IN
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Saint Anthony Memorial Health Centers
mi
from
Michigan City, IN
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Reid Hospital & Health Care Services, Incorporated
mi
from
Richmond, IN
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Reid Hospital & Health Care Services, Incorporated
mi
from
Richmond, IN
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
McFarland Clinic, PC
mi
from
Ames, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
McFarland Clinic, PC
mi
from
Ames, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
St. Luke's Hospital
mi
from
Cedar Rapids, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
St. Luke's Hospital
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Cedar Rapids Oncology Associates
mi
from
Cedar Rapids, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Cedar Rapids Oncology Associates
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Mercy Regional Cancer Center at Mercy Medical Center
mi
from
Cedar Rapids, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Mercy Regional Cancer Center at Mercy Medical Center
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Mercy Capitol Hospital
mi
from
Des Moines, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Mercy Capitol Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
John Stoddard Cancer Center at Iowa Methodist Medical Center
mi
from
Des Moines, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
John Stoddard Cancer Center at Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
mi
from
Des Moines, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Medical Oncology and Hematology Associates at Mercy Cancer Center
mi
from
Des Moines, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Medical Oncology and Hematology Associates at Mercy Cancer Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Mercy Cancer Center at Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Mercy Cancer Center at Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials